Research Paper Volume 12, Issue 12 pp 12119—12141

Serum proteomic predicts effectiveness and reveals potential biomarkers for complications in liver transplant patients

Figure 4. Serum proteomic profiling analysis for ITBL group, healthy controls (blue), transplant excellent patients (green) and ITBL patients (red). (A) Representative mass spectra of three samples in healthy controls, transplant excellent patients and ITBL patients in the mass range from 1000 to 10,000 Da. (B) Overall sum of the spectra in the mass range from 1000 to 10,000 Da obtained from ITBL group described above. (C) Bivariate plot of ITBL group with the most differentiated two peaks (m/z: 2088, 1950). (D) 3D plot of ITBL group. (E, G) Comparison of the spectra of two peaks in healthy controls, transplant excellent patients and ITBL patients. (F, H) ROC curves for two selected peaks with their AUC values. (I) Average expression levels of two selected peaks in healthy controls, transplant excellent patients and ITBL patients and their respective p-values. Values are expressed as mean ± SD. (***p < 0.001, **p < 0.01, *p < 0.05).